Effectiveness and Safety of Intra-articular SEMICAL GEL-B CROSS Therapy in Knee Osteoarthritis (SEM-ART1)
Key facts
- Who runs it
- Semikal Technology
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 102 people, planned
- Started
- 15 Jan 2025
- Ended
- 31 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cross-linked intra-articular hyaluronic acid
- Placebo
- Record updated
- 21 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Adults aged 18 and over, both male and female
- Diagnosed with clinical knee osteoarthritis according to the American College of
- Rheumatology (ACR) criteria, with Kellgren \& Lawrence stage II and III osteoarthritic findings on antero-posterior knee radiographs
- Able to provide written informed consent
Who cannot take part
- -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the effectiveness and safety of intra-articular injection of a cross-linked sodium hyaluronate; SEMICAL GEL-B CROSS, in knee osteoarthritis.
Read full original descriptionShow less
Primary objectives: The aim of this study is to obtain short- and long-term clinical data on the performance and safety of intra-articular injection of SEMICAL GEL B-CROSS, produced and marketed by Semical Biosurgery incorporated company, in knee osteoarthritis patients.
It is also aimed to monitoring known adverse events and complications, detecting previously unknown adverse events and complications, to identify and analyze emerging risks based on real-life data. Participants will receive intra-articular injection of either a cross-linked sodium hyaluronate (SEMICAL GEL-B CROSS); or placebo (isotonic saline solution) at baseline, and will be followed-up for one year to compare the effectiveness and safety of the given therapy.
The 2 groups in the trial
- Cross-linked intra-articular hyaluronic acidExisting treatment, for comparison
Cross-linked intra-articular hyaluronic acid (90 mg 3 ml cross-linked hyaluronic acid)
- PlaceboPlacebo, for comparison
Intra-articular isotonic saline solution (3 ml 0.9% isotonic saline) at the same dose as the treatment arm
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Effectiveness of Intra-articular Injection of a Cross-linked Sodium Hyaluronate in Knee Osteoarthritis: A Randomized, Prospective, Double-blind, Placebo-controlled, Cross-over, Post-marketing Clinical Follow-up Study
- Publications
- Record updated
- 21 August 2025